Difference between revisions of "Ovarian cancer - null regimens"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "https://www.thelancet.com/journals/lanonc/article/PII" to "https://doi.org/10.1016/")
m (Text replacement - "http://www.ncbi.nlm.nih.gov/pmc" to "https://www.ncbi.nlm.nih.gov/pmc")
 
(48 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
[[#top|Back to Top]]
 
[[#top|Back to Top]]
 
</div>
 
</div>
−
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the [[Ovarian cancer|main ovarian cancer page]] for current regimens.
+
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the [[Ovarian cancer|main ovarian cancer page]] for regimens that include active anticancer treatment.
  
 
{{TOC limit|limit=3}}
 
{{TOC limit|limit=3}}
Line 9: Line 9:
 
=Adjuvant therapy for early stage disease=
 
=Adjuvant therapy for early stage disease=
 
==Observation==
 
==Observation==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
−
!style="width: 20%"|Years of enrollment
+
!style="width: 20%"|Dates of enrollment
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|Comparator
 
!style="width: 20%"|Comparator
Line 21: Line 21:
 
|1976-1984
 
|1976-1984
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Melphalan_monotherapy_99|Melphalan]]
+
|[[#Melphalan_monotherapy_999|Melphalan]]
 
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
 
| style="background-color:#ffffbf" |Did not meet efficacy endpoints
 
|-
 
|-
Line 39: Line 39:
 
|1998-2006
 
|1998-2006
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Paclitaxel_monotherapy_99|Paclitaxel]]
+
|[[#Paclitaxel_monotherapy_999|Paclitaxel]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RR
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RR
 
|-
 
|-
Line 45: Line 45:
 
''<sup>1</sup>Reported efficacy for ACTION and ICON1 is based on the 2003 pooled update.''<br>
 
''<sup>1</sup>Reported efficacy for ACTION and ICON1 is based on the 2003 pooled update.''<br>
 
''No further treatment.''
 
''No further treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Preceding treatment====
 
====Preceding treatment====
−
*Young et al. 1990; ACTION; ICON1: [[Surgery#Ovarian_cancer_surgery|Surgery]]
+
*Young et al. 1990, ACTION, ICON1: [[Surgery#Ovarian_cancer_surgery|Surgery]]
−
*GOG-0175: [[Surgery#Ovarian_cancer_surgery|Surgery]], then [[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29|Carboplatin & Paclitaxel]] x 3
+
*GOG-0175: [[Surgery#Ovarian_cancer_surgery|Surgery]], then adjuvant [[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29|Carboplatin & Paclitaxel]] x 3
−
 
+
</div></div>
 
===References===
 
===References===
−
# Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990 Apr 12;322(15):1021-7. [https://doi.org/10.1056/NEJM199004123221501 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2181310 PubMed]
+
# Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990 Apr 12;322(15):1021-7. [https://doi.org/10.1056/NEJM199004123221501 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2181310/ PubMed]
−
# '''ACTION:''' Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; [[Study_Groups#EORTC|EORTC]]-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25. [https://academic.oup.com/jnci/article/95/2/113/2912344 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529344 PubMed]
+
# '''ACTION:''' Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; [[Study_Groups#EORTC|EORTC]]-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25. [https://academic.oup.com/jnci/article/95/2/113/2912344 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529344/ PubMed]
−
## '''Meta-analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; [[Study_Groups#EORTC|EORTC]] Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529343 PubMed]
+
## '''Meta-analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; [[Study_Groups#EORTC|EORTC]] Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529343/ PubMed]
−
# '''ICON1:''' Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; ICON. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. [https://academic.oup.com/jnci/article/95/2/125/2912345 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529345 PubMed] NCT00002477
+
# '''ICON1:''' Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; ICON. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. [https://academic.oup.com/jnci/article/95/2/125/2912345 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529345/ PubMed] [https://clinicaltrials.gov/study/NCT00002477 NCT00002477]
−
## '''Meta-analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; [[Study_Groups#EORTC|EORTC]] Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529343 PubMed]
+
## '''Meta-analysis:''' Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; [[Study_Groups#EORTC|EORTC]] Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. [https://academic.oup.com/jnci/article/95/2/105/2964945 link to original article] [https://pubmed.ncbi.nlm.nih.gov/12529343/ PubMed]
−
# '''GOG-0175:''' Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. [https://www.gynecologiconcology-online.net/article/S0090-8258(11)00188-0 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110746/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21529904 PubMed] NCT00003644
+
# '''GOG-0175:''' Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. [https://doi.org/10.1016/j.ygyno.2011.03.013 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110746/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/21529904/ PubMed] [https://clinicaltrials.gov/study/NCT00003644 NCT00003644]
  
 
=Maintenance after first-line therapy=
 
=Maintenance after first-line therapy=
 
==Observation==
 
==Observation==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
−
!style="width: 20%"|Years of enrollment
+
!style="width: 20%"|Dates of enrollment
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|Comparator
 
!style="width: 20%"|Comparator
Line 71: Line 72:
 
|1988-1997
 
|1988-1997
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Cisplatin_monotherapy_99|Cisplatin]]; IP
+
|[[#Cisplatin_monotherapy_999|Cisplatin]]; IP
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
|-
 
|-
Line 77: Line 78:
 
|1990-1997
 
|1990-1997
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Interferon_alfa-2a_monotherapy_99|IFN alfa-2a]]
+
|[[#Interferon_alfa-2a_monotherapy_999|IFN alfa-2a]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
|-
 
|-
Line 83: Line 84:
 
|1998-2002
 
|1998-2002
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Topotecan_monotherapy_99|Topotecan]]
+
|[[#Topotecan_monotherapy_999|Topotecan]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
|-
 
|-
Line 89: Line 90:
 
|1999-2002
 
|1999-2002
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Topotecan_monotherapy_99|Topotecan]]
+
|[[#Topotecan_monotherapy_999|Topotecan]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
|-
 
|-
Line 95: Line 96:
 
|1999-2006
 
|1999-2006
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Paclitaxel_monotherapy_99|Paclitaxel]]
+
|[[#Paclitaxel_monotherapy_999|Paclitaxel]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS
 
|-
 
|-
−
|[https://doi.org/10.1200/jco.2008.17.8400 Berek et al. 2008 (OVA-Gy-17)]
+
|[https://doi.org/10.1200/JCO.2013.50.5669 Vergote et al. 2013 (EORTC 55041)]
−
|2002-NR
+
|2005-2008
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Oregovomab_monotherapy_77|Oregovomab]]
+
|[[#Erlotinib_monotherapy_999|Erlotinib]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTR
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 12.4 vs 12.7 mo<br>(HR 0.95, 95% CI 0.81-1.11)
 
|-
 
|-
−
|[https://doi.org/10.1200/JCO.2013.50.5669 Vergote et al. 2013 (EORTC 55041)]
+
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746779/ Copeland et al. 2022 (GOG 0212)]
−
|2005-2008 (C)
+
|2005-2014
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Erlotinib_monotherapy_99|Erlotinib]]
+
|1. [[#Paclitaxel_monotherapy_999|Paclitaxel]]<br>2. [[#Paclitaxel_poliglumex_monotherapy_999|Paclitaxel poliglumex]]
−
| style="background-color:#ffffbf" |Did not meet primary endpoint of PFS<br>Median PFS: 12.4 vs 12.7 mo<br>(HR 0.95, 95% CI 0.81-1.11)
+
| style="background-color:#ffffbf" |Did not meet primary endpoint of OS
 
|-
 
|-
 
|}
 
|}
 
''No further treatment.''
 
''No further treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Preceding treatment====
 
====Preceding treatment====
−
*AGO-OVAR 7: [[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29_3|TC]] x 6-10
+
*AGO-OVAR 7: First-line [[Ovarian_cancer#Carboplatin_.26_Paclitaxel_.28CP.29_3|TC]] x 6-10
−
*EORTC 55041: Debulking surgery ([[Surgery#Primary_debulking_surgery|primary]] or [[Surgery#Interval_debulking_surgery|interval]]) & [[Regimen_classes#Platinum-based_regimen|platinum-based chemotherapy]] x 6 to 9, with SD or better
+
*EORTC 55041: Debulking surgery ([[Surgery#Primary_debulking_surgery|primary]] or [[Surgery#Interval_debulking_surgery|interval]]) & First-line [[Regimen_classes#Platinum-based_regimen|platinum-based chemotherapy]] x 6 to 9, with SD or better
−
 
+
*GOG 0212: First-line [[Regimen_classes#Platinum-taxane-based_regimen|platinum-taxane-based chemotherapy]]
 +
</div></div>
 
===References===
 
===References===
−
# '''EORTC 55875:''' Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203. [https://ijgc.bmj.com/content/13/Suppl_2/196.abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/14656280 PubMed]
+
# '''EORTC 55875:''' Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203. [https://ijgc.bmj.com/content/13/Suppl_2/196.abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/14656280/ PubMed]
−
# '''MITO-1:''' De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004 Jul 1;22(13):2635-42. [https://doi.org/10.1200/JCO.2004.09.088 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15226331 PubMed]
+
# '''MITO-1:''' De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004 Jul 1;22(13):2635-42. [https://doi.org/10.1200/JCO.2004.09.088 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15226331/ PubMed]
−
# Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ, Perren TJ. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004 Aug 16;91(4):621-6. [https://www.nature.com/articles/6602037 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364769/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/15305182 PubMed]
+
# Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ, Perren TJ. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004 Aug 16;91(4):621-6. [https://doi.org/10.1038/sj.bjc.6602037 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364769/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/15305182/ PubMed]
−
# '''AGO-OVAR 7:''' Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. [https://academic.oup.com/jnci/article/98/15/1036/2521688 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16882940 PubMed] NCT00006454
+
# '''AGO-OVAR 7:''' Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. [https://academic.oup.com/jnci/article/98/15/1036/2521688 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16882940/ PubMed] [https://clinicaltrials.gov/study/NCT00006454 NCT00006454]
−
# '''OVA-Gy-17:''' Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25. Epub 2008 Dec 15. [https://doi.org/10.1200/jco.2008.17.8400 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19075271/ PubMed] NCT00050375
+
# '''After-6 protocol 1:''' Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009 Oct 1;27(28):4642-8. Epub 2009 Aug 24. [https://doi.org/10.1200/JCO.2009.21.9691 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19704064/ PubMed]
−
# '''After-6 protocol 1:''' Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009 Oct 1;27(28):4642-8. Epub 2009 Aug 24. [https://doi.org/10.1200/JCO.2009.21.9691 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19704064 PubMed]
 
 
<!-- Presented as an oral abstract at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. -->
 
<!-- Presented as an oral abstract at the 48th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 1-5, 2012. -->
−
# '''EORTC 55041:''' Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014 Feb 1;32(4):320-6. Epub 2013 Dec 23. [https://doi.org/10.1200/JCO.2013.50.5669 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24366937 PubMed] NCT00263822
+
# '''EORTC 55041:''' Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014 Feb 1;32(4):320-6. Epub 2013 Dec 23. [https://doi.org/10.1200/JCO.2013.50.5669 link to original article] [https://pubmed.ncbi.nlm.nih.gov/24366937/ PubMed] [https://clinicaltrials.gov/study/NCT00263822 NCT00263822]
 +
# '''GOG 0212:''' Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022 Dec 10;40(35):4119-4128. Epub 2022 Jun 27. [https://doi.org/10.1200/jco.22.00146 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746779/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35759733/ PubMed] [https://clinicaltrials.gov/study/NCT00108745 NCT00108745]
  
 
==Placebo==
 
==Placebo==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
−
!style="width: 20%"|Years of enrollment
+
!style="width: 20%"|Dates of enrollment
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|Comparator
 
!style="width: 20%"|Comparator
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 
|-
 
|-
−
|[https://www.gynecologiconcology-online.net/article/S0090-8258(05)01122-4 Hirte et al. 2006]
+
|[https://doi.org/10.1016/j.ygyno.2005.12.020 Hirte et al. 2006]
−
|1998-1999
+
|1998-05-05 to 1999-09-20
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Tanomastat_monotherapy_77|Tanomastat]]
+
|[[#Tanomastat_monotherapy_999|Tanomastat]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTP
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTP
 
|-
 
|-
Line 145: Line 148:
 
|2002-NR
 
|2002-NR
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Oregovomab_monotherapy_77|Oregovomab]]
+
|[[#Oregovomab_monotherapy_999|Oregovomab]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTR
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of TTR
 
|-
 
|-
Line 151: Line 154:
 
|2006-2009
 
|2006-2009
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Abagovomab_monotherapy_77|Abagovomab]]
+
|[[#Abagovomab_monotherapy_999|Abagovomab]]
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
 
| style="background-color:#ffffbf" |Did not meet primary endpoint of RFS
 
|-
 
|-
 
|[https://doi.org/10.1200/jco.2014.55.7348 Du Bois et al. 2014 (AGO-OVAR 16)]
 
|[https://doi.org/10.1200/jco.2014.55.7348 Du Bois et al. 2014 (AGO-OVAR 16)]
−
|2009-2010
+
|2009-06 to 2010-08
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Ovarian_cancer#Pazopanib_monotherapy|Pazopanib]]
 
|[[Ovarian_cancer#Pazopanib_monotherapy|Pazopanib]]
Line 164: Line 167:
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Ovarian_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
 
|[[Ovarian_cancer,_BRCA-mutated#Olaparib_monotherapy|Olaparib]]
 +
|style="background-color:#d73027"|Inferior OS<sup>1</sup>
 +
|-
 +
|[https://doi.org/10.1056/NEJMoa1910962 González-Martín et al. 2019 (PRIMA<sub>OV</sub>)]
 +
|2016-2018
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[Ovarian_cancer#Niraparib_monotherapy|Niraparib]]
 +
|style="background-color:#d73027"|Inferior PFS
 +
|-
 +
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746782/ Monk et al. 2022 (ATHENA-MONO)]
 +
|2018-2020
 +
|style="background-color:#1a9851"|Phase 3 (C)
 +
|[[Ovarian_cancer#Rucaparib_monotherapy|Rucaparib]]
 
|style="background-color:#d73027"|Inferior PFS
 
|style="background-color:#d73027"|Inferior PFS
 
|-
 
|-
 
|}
 
|}
 +
''<sup>1</sup>Reported efficacy is based on the 2022 update; the OS result did not meet the authors' predefined level of statistical significance, which was based on P-value.''<br>
 
''No active antineoplastic treatment after initial treatment.''
 
''No active antineoplastic treatment after initial treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Preceding treatment====
 
====Preceding treatment====
−
*MIMOSA: Debulking surgery, then platinum-taxane-based chemotherapy x 6 to 8, with CR
+
*MIMOSA: [[Surgery#Primary_debulking_surgery|Debulking surgery]], then first-line [[Regimen_classes#Platinum-based_regimen|platinum-taxane-based chemotherapy]] x 6 to 8, with CR
−
*AGO-OVAR 16: Debulking surgery (primary or interval) & platinum-taxane-based chemotherapy for at least 5 cycles, with SD or better
+
*AGO-OVAR 16: [[Surgery#Primary_debulking_surgery|Debulking surgery (primary or interval)]], then first-line [[Regimen_classes#Platinum-based_regimen|platinum-taxane-based chemotherapy]] for at least 5 cycles, with SD or better
 +
*PRIMA<sub>OV</sub>: First-line [[Regimen_classes#Platinum-based_regimen|Platinum-containing chemotherapy]]; neither specific agents, combinations, nor doses are specified in the protocol.
 +
*ATHENA-MONO: First-line [[Regimen_classes#Platinum_doublet|Platinum doublet chemotherapy]]
 +
</div></div>
  
 
===References===
 
===References===
−
# Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L; National Cancer Institute of Canada Clinical Trials Group. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group study. Gynecol Oncol. 2006 Aug;102(2):300-8. Epub 2006 Jan 25. [https://www.gynecologiconcology-online.net/article/S0090-8258(05)01122-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16442153 PubMed]
+
# Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L; National Cancer Institute of Canada Clinical Trials Group. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group study. Gynecol Oncol. 2006 Aug;102(2):300-8. Epub 2006 Jan 25. [https://doi.org/10.1016/j.ygyno.2005.12.020 link to original article] [https://pubmed.ncbi.nlm.nih.gov/16442153/ PubMed]
−
# '''OVA-Gy-17:''' Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25. Epub 2008 Dec 15. [https://doi.org/10.1200/jco.2008.17.8400 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19075271/ PubMed] NCT00050375
+
# '''OVA-Gy-17:''' Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25. Epub 2008 Dec 15. [https://doi.org/10.1200/jco.2008.17.8400 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19075271/ PubMed] [https://clinicaltrials.gov/study/NCT00050375 NCT00050375]
−
# '''MIMOSA:''' Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554-61. Epub 2013 Mar 11. [https://doi.org/10.1200/JCO.2012.46.4057 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795662/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23478059 PubMed] NCT00418574
+
# '''MIMOSA:''' Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554-61. Epub 2013 Mar 11. [https://doi.org/10.1200/JCO.2012.46.4057 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5795662/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/23478059/ PubMed] [https://clinicaltrials.gov/study/NCT00418574 NCT00418574]
 
<!-- # '''Abstract:''' Andreas Du Bois, Anne Floquet, Jae Weon Kim, Jörn Rau, Jose Maria Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Mansoor Raza Mirza, Bradley J. Monk, Pauline Wimberger, Isabelle Ray-Coquard, Rongyu Zang, Ivan Diaz-Padilla, Klaus H. Baumann, Jae Hoon Kim, Philipp Harter. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). 2013 ASCO Annual Meeting abstract LBA5503. [http://meetinglibrary.asco.org/content/115898-132 link to abstract] -->
 
<!-- # '''Abstract:''' Andreas Du Bois, Anne Floquet, Jae Weon Kim, Jörn Rau, Jose Maria Del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Mansoor Raza Mirza, Bradley J. Monk, Pauline Wimberger, Isabelle Ray-Coquard, Rongyu Zang, Ivan Diaz-Padilla, Klaus H. Baumann, Jae Hoon Kim, Philipp Harter. Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16). 2013 ASCO Annual Meeting abstract LBA5503. [http://meetinglibrary.asco.org/content/115898-132 link to abstract] -->
−
# '''AGO-OVAR 16:''' du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. [https://doi.org/10.1200/jco.2014.55.7348 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/25225436 PubMed] NCT00866697
+
# '''AGO-OVAR 16:''' du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. [https://doi.org/10.1200/jco.2014.55.7348 link to original article] [https://pubmed.ncbi.nlm.nih.gov/25225436/ PubMed] [https://clinicaltrials.gov/study/NCT00866697 NCT00866697]
−
## '''Subgroup analysis:''' Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. [https://ijgc.bmj.com/content/28/1/2.abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/26588236 PubMed]
+
## '''Subgroup analysis:''' Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. [https://ijgc.bmj.com/content/28/1/2.abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/26588236/ PubMed]
−
## '''Update:''' Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. Epub 2019 Sep 10. [https://www.gynecologiconcology-online.net/article/S0090-8258(19)31476-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31519320 PubMed]
+
## '''Update:''' Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. Epub 2019 Sep 10. [https://doi.org/10.1016/j.ygyno.2019.08.024 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31519320/ PubMed]
−
# '''SOLO1:''' Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21. [https://doi.org/10.1056/NEJMoa1810858 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/30345884 PubMed] NCT01844986
+
# '''SOLO1:''' Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21. [https://doi.org/10.1056/NEJMoa1810858 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30345884/ PubMed] [https://clinicaltrials.gov/study/NCT01844986 NCT01844986]
 
## '''HRQoL analysis:''' Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. Epub 2021 Apr 13. [https://doi.org/10.1016/s1470-2045(21)00098-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/33862001/ PubMed]
 
## '''HRQoL analysis:''' Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. Epub 2021 Apr 13. [https://doi.org/10.1016/s1470-2045(21)00098-x link to original article] [https://pubmed.ncbi.nlm.nih.gov/33862001/ PubMed]
 
## '''Update:''' Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1721-1731. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539. [https://doi.org/10.1016/s1470-2045(21)00531-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34715071/ PubMed]
 
## '''Update:''' Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1721-1731. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539. [https://doi.org/10.1016/s1470-2045(21)00531-3 link to original article] [https://pubmed.ncbi.nlm.nih.gov/34715071/ PubMed]
−
#'''ATHENA:''' NCT03522246
+
## '''Update:''' DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9. [https://doi.org/10.1200/jco.22.01549 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc9870219/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/36082969/ PubMed]
−
#'''MAMOC:''' NCT04227522
+
# '''PRIMA<sub>OV</sub>:''' González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. Epub 2019 Sep 28. [https://doi.org/10.1056/NEJMoa1910962 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31562799/ PubMed] [https://clinicaltrials.gov/study/NCT02655016 NCT02655016]
−
#'''MATAO:''' NCT04111978
+
##'''Update:''' González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023 Aug;189:112908. Epub 2023 May 3. [https://doi.org/10.1016/j.ejca.2023.04.024 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37263896/ PubMed]
 +
# '''ATHENA-MONO:''' Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Dec 1;40(34):3952-3964. Epub 2022 Jun 6. [https://doi.org/10.1200/jco.22.01003 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746782/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/35658487/ PubMed] [https://clinicaltrials.gov/study/NCT03522246 NCT03522246]
 +
#'''MAMOC:''' [https://clinicaltrials.gov/study/NCT04227522 NCT04227522]
 +
#'''MATAO:''' [https://clinicaltrials.gov/study/NCT04111978 NCT04111978]
  
 
=Maintenance after second-line therapy for platinum-sensitive disease=
 
=Maintenance after second-line therapy for platinum-sensitive disease=
 
==Placebo==
 
==Placebo==
−
 
+
<div class="toccolours" style="background-color:#eeeeee">
 
===Regimen===
 
===Regimen===
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
{| class="wikitable sortable" style="width: 100%; text-align:center;"  
 
!style="width: 20%"|Study
 
!style="width: 20%"|Study
−
!style="width: 20%"|Years of enrollment
+
!style="width: 20%"|Dates of enrollment
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
 
!style="width: 20%"|Comparator
 
!style="width: 20%"|Comparator
Line 201: Line 224:
 
|2007-2011
 
|2007-2011
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Cediranib_monotherapy_77|Cediranib]]
+
|[[#Cediranib_monotherapy_777|Cediranib]]
 
|style="background-color:#d73027"|Inferior PFS
 
|style="background-color:#d73027"|Inferior PFS
 
|-
 
|-
Line 207: Line 230:
 
|2008-2010
 
|2008-2010
 
|style="background-color:#1a9851"|Randomized Phase 2 (C)
 
|style="background-color:#1a9851"|Randomized Phase 2 (C)
−
|[[Ovarian_cancer#Olaparib_monotherapy_3|Olaparib]]
+
|[[Ovarian_cancer#Olaparib_monotherapy|Olaparib]]
 
| style="background-color:#fee08b" |Might have inferior OS<sup>1</sup>
 
| style="background-color:#fee08b" |Might have inferior OS<sup>1</sup>
 
|-
 
|-
Line 217: Line 240:
 
|-
 
|-
 
|[https://doi.org/10.1016/S1470-2045(17)30469-2 Pujade-Lauraine et al. 2017 (SOLO2)]
 
|[https://doi.org/10.1016/S1470-2045(17)30469-2 Pujade-Lauraine et al. 2017 (SOLO2)]
−
|2013-2014
+
|2013-09-03 to 2014-11-21
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Ovarian_cancer,_BRCA-mutated#Olaparib_monotherapy_3|Olaparib]]
 
|[[Ovarian_cancer,_BRCA-mutated#Olaparib_monotherapy_3|Olaparib]]
Line 226: Line 249:
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|[[Ovarian_cancer#Rucaparib_monotherapy_2|Rucaparib]]
 
|[[Ovarian_cancer#Rucaparib_monotherapy_2|Rucaparib]]
 +
|style="background-color:#d73027"|Inferior PFS
 +
|-
 +
|[https://doi.org/10.1016/j.annonc.2023.09.3110 Pujade-Lauraine et al. 2023 (OReO)]
 +
|2017-06-28 to 2021-02-10
 +
|style="background-color:#1a9851"|Phase 3b (C)
 +
|[[Ovarian_cancer#Olaparib_monotherapy|Olaparib]]
 
|style="background-color:#d73027"|Inferior PFS
 
|style="background-color:#d73027"|Inferior PFS
 
|-
 
|-
 
|[https://doi.org/10.1200/jco.21.01511 Li et al. 2022 (FZOCUS-2)]
 
|[https://doi.org/10.1200/jco.21.01511 Li et al. 2022 (FZOCUS-2)]
−
|2019-2020
+
|2019-04-30 to 2020-01-10
 
|style="background-color:#1a9851"|Phase 3 (C)
 
|style="background-color:#1a9851"|Phase 3 (C)
−
|[[#Fuzuloparib_monotherapy_77|Fuzuloparib]]
+
|[[#Fuzuloparib_monotherapy_777|Fuzuloparib]]
 
|style="background-color:#d73027"|Inferior PFS
 
|style="background-color:#d73027"|Inferior PFS
 
|-
 
|-
Line 238: Line 267:
 
''<sup>2</sup>Reported efficacy for SOLO2 is based on the 2021 update.''<br>
 
''<sup>2</sup>Reported efficacy for SOLO2 is based on the 2021 update.''<br>
 
''No further active antineoplastic treatment.''
 
''No further active antineoplastic treatment.''
 +
<div class="toccolours" style="background-color:#cbd5e7">
 
====Preceding treatment====
 
====Preceding treatment====
−
*[[Regimen_classes#Platinum-based_regimen|Platinum-based chemotherapy]]
+
*Second-line [[Regimen_classes#Platinum-based_regimen|platinum-based chemotherapy]]
 +
</div></div>
  
 
===References===
 
===References===
−
# '''Study 19:''' Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. [https://doi.org/10.1056/NEJMoa1105535 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/22452356 PubMed] NCT00753545
+
# '''Study 19:''' Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. Epub 2012 Mar 27. [https://doi.org/10.1056/NEJMoa1105535 link to original article] [https://pubmed.ncbi.nlm.nih.gov/22452356/ PubMed] [https://clinicaltrials.gov/study/NCT00753545 NCT00753545]
−
## '''Update:''' Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. Epub 2016 Sep 8. [https://doi.org/10.1016/S1470-2045(16)30376-X link to orignal article] [https://pubmed.ncbi.nlm.nih.gov/27617661 PubMed]
+
## '''Update:''' Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. Epub 2016 Sep 8. [https://doi.org/10.1016/S1470-2045(16)30376-X link to orignal article] [https://pubmed.ncbi.nlm.nih.gov/27617661/ PubMed]
−
## '''Update:''' Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075-1085. Epub 2018 Oct 24. [https://www.nature.com/articles/s41416-018-0271-y link to original article] [https://pubmed.ncbi.nlm.nih.gov/30353045 PubMed]
+
## '''HRQoL analysis:''' Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22;115(11):1313-1320. Epub 2016 Nov 8. [https://doi.org/10.1038/bjc.2016.348 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc5129820/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/27824811/ PubMed]
−
# '''ICON6:''' Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB; ICON. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-1074. Erratum in: Lancet. 2016 Apr 23;387(10029):1722. [https://doi.org/10.1016/S0140-6736(15)01167-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27025186 PubMed] NCT00532194
+
## '''Update:''' Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075-1085. Epub 2018 Oct 24. [https://doi.org/10.1038/s41416-018-0271-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6219499/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30353045/ PubMed]
 +
# '''ICON6:''' Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB; ICON. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-1074. Erratum in: Lancet. 2016 Apr 23;387(10029):1722. [https://doi.org/10.1016/S0140-6736(15)01167-8 link to original article] [https://pubmed.ncbi.nlm.nih.gov/27025186/ PubMed] [https://clinicaltrials.gov/study/NCT00532194 NCT00532194]
 
## '''Update:''' Ledermann JA, Embleton-Thirsk AC, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Oza A, Vaughan M, Friedlander M, González-Martín A, Deane E, Popoola B, Farrelly L, Swart AM, Kaplan RS, Parmar MKB; ICON6 collaborators. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open. 2021 Apr;6(2):100043. Epub 2021 Feb 18. [https://doi.org/10.1016/j.esmoop.2020.100043 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7903311/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33610123/ PubMed]
 
## '''Update:''' Ledermann JA, Embleton-Thirsk AC, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Oza A, Vaughan M, Friedlander M, González-Martín A, Deane E, Popoola B, Farrelly L, Swart AM, Kaplan RS, Parmar MKB; ICON6 collaborators. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open. 2021 Apr;6(2):100043. Epub 2021 Feb 18. [https://doi.org/10.1016/j.esmoop.2020.100043 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7903311/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/33610123/ PubMed]
−
# '''NOVA:''' Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. [https://doi.org/10.1056/NEJMoa1611310 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27717299 PubMed] NCT01847274
+
# '''NOVA:''' Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. [https://doi.org/10.1056/NEJMoa1611310 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/27717299/ PubMed] [https://clinicaltrials.gov/study/NCT01847274 NCT01847274]
−
## '''Subgroup analysis:''' Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. Epub 2019 Jun 7. [https://doi.org/10.1200/JCO.18.02238 link to original article] [https://pubmed.ncbi.nlm.nih.gov/31173551 PubMed]
+
## '''PRO analysis:''' Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug;19(8):1117-1125. Epub 2018 Jul 17. [https://doi.org/10.1016/s1470-2045(18)30333-4 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30026000/ PubMed]
−
# '''SOLO2:''' Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25. [https://doi.org/10.1016/S1470-2045(17)30469-2 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/28754483 PubMed] NCT01874353
+
## '''Subgroup analysis:''' Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. Epub 2019 Jun 7. [https://doi.org/10.1200/JCO.18.02238 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc6839909/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/31173551/ PubMed]
 +
## '''Update:''' Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Casado Herráez A, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020 Nov;159(2):442-448. Epub 2020 Sep 25. [https://doi.org/10.1016/j.ygyno.2020.09.006 link to original article] [https://pubmed.ncbi.nlm.nih.gov/32981695/ PubMed]
 +
# '''SOLO2:''' Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25. [https://doi.org/10.1016/S1470-2045(17)30469-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/28754483/ PubMed] [https://clinicaltrials.gov/study/NCT01874353 NCT01874353]
 
## '''Update:''' Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620-631. Epub 2021 Mar 18. [https://doi.org/10.1016/s1470-2045(21)00073-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33743851/ PubMed]
 
## '''Update:''' Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620-631. Epub 2021 Mar 18. [https://doi.org/10.1016/s1470-2045(21)00073-5 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33743851/ PubMed]
−
# '''ARIEL3:''' Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12. [https://doi.org/10.1016/S0140-6736(17)32440-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901715/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28916367 PubMed] NCT01968213
+
# '''ARIEL3:''' Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12. [https://doi.org/10.1016/S0140-6736(17)32440-6 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901715/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28916367/ PubMed] [https://clinicaltrials.gov/study/NCT01968213 NCT01968213]
−
#'''FZOCUS-2:''' Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. J Clin Oncol. 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11. [https://doi.org/10.1200/jco.21.01511 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35404684/ PubMed] NCT03863860
+
## '''Update:''' Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 May;21(5):710-722. [https://doi.org/10.1016/s1470-2045(20)30061-9 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8210534/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32359490/ PubMed]
−
#'''OReO:''' NCT03106987
+
## '''Update:''' Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol. 2020 Oct 20;38(30):3494-3505. Epub 2020 Aug 24. [https://doi.org/10.1200/jco.19.03107 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7571791/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/32840418/ PubMed]
 +
##'''PRO analysis:''' Peipert JD, Goble S, Isaacson J, Tang X, Wallace K, Coleman RL, Ledermann JA, Cella D. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial. Gynecol Oncol. 2023 Aug;175:1-7. Epub 2023 May 30. [https://doi.org/10.1016/j.ygyno.2023.05.060 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37262961/ PubMed]
 +
#'''FZOCUS-2:''' Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. J Clin Oncol. 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11. [https://doi.org/10.1200/jco.21.01511 link to original article] [https://pubmed.ncbi.nlm.nih.gov/35404684/ PubMed] [https://clinicaltrials.gov/study/NCT03863860 NCT03863860]
 +
#'''OReO:''' Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023 Dec;34(12):1152-1164. Epub 2023 Oct 4. [https://doi.org/10.1016/j.annonc.2023.09.3110 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37797734/ PubMed] [https://clinicaltrials.gov/study/NCT03106987 NCT03106987]
  
 
[[Category:Ovarian cancer regimens]]
 
[[Category:Ovarian cancer regimens]]

Latest revision as of 12:20, 23 June 2024

Back to Top

The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main ovarian cancer page for regimens that include active anticancer treatment.


Adjuvant therapy for early stage disease

Observation

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Young et al. 1990 1976-1984 Phase 3 (C) Melphalan Did not meet efficacy endpoints
Trimbos et al. 2003 (ACTION) 1990-2000 Phase 3 (C) Platinum-based chemotherapy Inferior OS1
Colombo et al. 2003 (ICON1) 1991-2000 Phase 3 (C) Platinum-based chemotherapy Inferior OS1
Mannel et al. 2011 (GOG-0175) 1998-2006 Phase 3 (C) Paclitaxel Did not meet primary endpoint of RR

1Reported efficacy for ACTION and ICON1 is based on the 2003 pooled update.
No further treatment.

Preceding treatment

References

  1. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990 Apr 12;322(15):1021-7. link to original article PubMed
  2. ACTION: Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, Franchi M, Tateo S, Zanetta G, Scarfone G, Giurgea L, Timmers P, Coens C, Pecorelli S; EORTC-ACTION collaborators. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003 Jan 15;95(2):113-25. link to original article PubMed
    1. Meta-analysis: Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; EORTC Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. link to original article PubMed
  3. ICON1: Colombo N, Guthrie D, Chiari S, Parmar M, Qian W, Swart AM, Torri V, Williams C, Lissoni A, Bonazzi C; ICON. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst. 2003 Jan 15;95(2):125-32. link to original article PubMed NCT00002477
    1. Meta-analysis: Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaborative Ovarian Neoplasm 1; EORTC Collaborators-Adjuvant ChemoTherapy un Ovarian Neoplasm. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003 Jan 15;95(2):105-12. link to original article PubMed
  4. GOG-0175: Mannel RS, Brady MF, Kohn EC, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, Michael H. A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Jul;122(1):89-94. Epub 2011 May 6. link to original article link to PMC article PubMed NCT00003644

Maintenance after first-line therapy

Observation

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Piccart et al. 2003 (EORTC 55875) 1988-1997 Phase 3 (C) Cisplatin; IP Did not meet primary endpoint of OS
Hall et al. 2004 1990-1997 Phase 3 (C) IFN alfa-2a Did not meet primary endpoint of OS
De Placido et al. 2004 (MITO-1) 1998-2002 Phase 3 (C) Topotecan Did not meet primary endpoint of PFS
Pfisterer et al. 2006 (AGO-OVAR 7) 1999-2002 Phase 3 (C) Topotecan Did not meet primary endpoint of OS
Pecorelli et al. 2009 (After-6 protocol 1) 1999-2006 Phase 3 (C) Paclitaxel Did not meet primary endpoint of PFS
Vergote et al. 2013 (EORTC 55041) 2005-2008 Phase 3 (C) Erlotinib Did not meet primary endpoint of PFS
Median PFS: 12.4 vs 12.7 mo
(HR 0.95, 95% CI 0.81-1.11)
Copeland et al. 2022 (GOG 0212) 2005-2014 Phase 3 (C) 1. Paclitaxel
2. Paclitaxel poliglumex 		Did not meet primary endpoint of OS

No further treatment.

Preceding treatment

References

  1. EORTC 55875: Piccart MJ, Floquet A, Scarfone G, Willemse PH, Emerich J, Vergote I, Giurgea L, Coens C, Awada A, Vermorken JB. Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:196-203. link to original article PubMed
  2. MITO-1: De Placido S, Scambia G, Di Vagno G, Naglieri E, Lombardi AV, Biamonte R, Marinaccio M, Cartenì G, Manzione L, Febbraro A, De Matteis A, Gasparini G, Valerio MR, Danese S, Perrone F, Lauria R, De Laurentiis M, Greggi S, Gallo C, Pignata S. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J Clin Oncol. 2004 Jul 1;22(13):2635-42. link to original article PubMed
  3. Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, Poole C, Crawford M, Hancock B, Selby PJ, Perren TJ. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004 Aug 16;91(4):621-6. link to original article link to PMC article PubMed
  4. AGO-OVAR 7: Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, Lortholary A, Olbricht S, Stähle A, Jackisch C, Hardy-Bessard AC, Möbus V, Quaas J, Richter B, Schröder W, Geay JF, Lück HJ, Kuhn W, Meden H, Nitz U, Pujade-Lauraine E; AGO-OVAR; GINECO. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006 Aug 2;98(15):1036-45. link to original article PubMed NCT00006454
  5. After-6 protocol 1: Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, Ballardini M, Nanni O, Conte P; After 6 Italian Cooperative Group. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009 Oct 1;27(28):4642-8. Epub 2009 Aug 24. link to original article PubMed
  6. EORTC 55041: Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J Clin Oncol. 2014 Feb 1;32(4):320-6. Epub 2013 Dec 23. link to original article PubMed NCT00263822
  7. GOG 0212: Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang HQ, Cella D, O'Malley DM, Street DG, Tewari KS, Bender DP, Morris RT, Lowery WJ, Miller DS, Dewdney SB, Spirtos NM, Lele SB, Guntupalli S, Ueland FR, Glaser GE, Mannel RS, DiSaia PJ. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. J Clin Oncol. 2022 Dec 10;40(35):4119-4128. Epub 2022 Jun 27. link to original article link to PMC article PubMed NCT00108745

Placebo

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Hirte et al. 2006 1998-05-05 to 1999-09-20 Phase 3 (C) Tanomastat Did not meet primary endpoint of TTP
Berek et al. 2008 (OVA-Gy-17) 2002-NR Phase 3 (C) Oregovomab Did not meet primary endpoint of TTR
Sabbatini et al. 2013 (MIMOSA) 2006-2009 Phase 3 (C) Abagovomab Did not meet primary endpoint of RFS
Du Bois et al. 2014 (AGO-OVAR 16) 2009-06 to 2010-08 Phase 3 (C) Pazopanib Inferior PFS
Moore et al. 2018 (SOLO1) 2013-2015 Phase 3 (C) Olaparib Inferior OS1
González-Martín et al. 2019 (PRIMAOV) 2016-2018 Phase 3 (C) Niraparib Inferior PFS
Monk et al. 2022 (ATHENA-MONO) 2018-2020 Phase 3 (C) Rucaparib Inferior PFS

1Reported efficacy is based on the 2022 update; the OS result did not meet the authors' predefined level of statistical significance, which was based on P-value.
No active antineoplastic treatment after initial treatment.

Preceding treatment

References

  1. Hirte H, Vergote IB, Jeffrey JR, Grimshaw RN, Coppieters S, Schwartz B, Tu D, Sadura A, Brundage M, Seymour L; National Cancer Institute of Canada Clinical Trials Group. A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group study. Gynecol Oncol. 2006 Aug;102(2):300-8. Epub 2006 Jan 25. link to original article PubMed
  2. OVA-Gy-17: Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol. 2009 Jan 20;27(3):418-25. Epub 2008 Dec 15. link to original article PubMed NCT00050375
  3. MIMOSA: Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013 Apr 20;31(12):1554-61. Epub 2013 Mar 11. link to original article link to PMC article PubMed NCT00418574
  4. AGO-OVAR 16: du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. Epub 2014 Sep 15. link to original article PubMed NCT00866697
    1. Subgroup analysis: Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2018 Jan;28(1):2-10. link to original article PubMed
    2. Update: Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019 Nov;155(2):186-191. Epub 2019 Sep 10. link to original article PubMed
  5. SOLO1: Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018 Dec 27;379(26):2495-2505. Epub 2018 Oct 21. link to original article PubMed NCT01844986
    1. HRQoL analysis: Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. Epub 2021 Apr 13. link to original article PubMed
    2. Update: Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1721-1731. Epub 2021 Oct 26. Erratum in: Lancet Oncol. 2021 Dec;22(12):e539. link to original article PubMed
    3. Update: DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2023 Jan 20;41(3):609-617. Epub 2022 Sep 9. link to original article link to PMC article PubMed
  6. PRIMAOV: González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2019 Dec 19;381(25):2391-2402. Epub 2019 Sep 28. link to original article PubMed NCT02655016
    1. Update: González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023 Aug;189:112908. Epub 2023 May 3. link to original article PubMed
  7. ATHENA-MONO: Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J Clin Oncol. 2022 Dec 1;40(34):3952-3964. Epub 2022 Jun 6. link to original article link to PMC article PubMed NCT03522246
  8. MAMOC: NCT04227522
  9. MATAO: NCT04111978

Maintenance after second-line therapy for platinum-sensitive disease

Placebo

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Ledermann et al. 2016 (ICON6) 2007-2011 Phase 3 (C) Cediranib Inferior PFS
Ledermann et al. 2012 (Study 19) 2008-2010 Randomized Phase 2 (C) Olaparib Might have inferior OS1
Mirza et al. 2016 (NOVA) 2013-NR Phase 3 (C) Niraparib Inferior PFS
Pujade-Lauraine et al. 2017 (SOLO2) 2013-09-03 to 2014-11-21 Phase 3 (C) Olaparib Seems to have inferior OS2
Coleman et al. 2017 (ARIEL3) 2014-2016 Phase 3 (C) Rucaparib Inferior PFS
Pujade-Lauraine et al. 2023 (OReO) 2017-06-28 to 2021-02-10 Phase 3b (C) Olaparib Inferior PFS
Li et al. 2022 (FZOCUS-2) 2019-04-30 to 2020-01-10 Phase 3 (C) Fuzuloparib Inferior PFS

1Reported efficacy for Study 19 is based on the 2018 update; although p=0.02, the authors state that "the predefined threshold for statistical significance was not met."
2Reported efficacy for SOLO2 is based on the 2021 update.
No further active antineoplastic treatment.

Preceding treatment

References

  1. Study 19: Ledermann J1, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12;366(15):1382-92. Epub 2012 Mar 27. link to original article PubMed NCT00753545
    1. Update: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1579-1589. Epub 2016 Sep 8. link to orignal article PubMed
    2. HRQoL analysis: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Bennett B, Parry D, Spencer S, Mann H, Matulonis U. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22;115(11):1313-1320. Epub 2016 Nov 8. link to original article link to PMC article PubMed
    3. Update: Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Shirinkin V, Selle F, Fielding A, Lowe ES, McMurtry EL, Spencer S, Rowe P, Mann H, Parry D, Ledermann J. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 Oct;119(9):1075-1085. Epub 2018 Oct 24. link to original article link to PMC article PubMed
  2. ICON6: Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, González-Martín A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB; ICON. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Mar 12;387(10023):1066-1074. Erratum in: Lancet. 2016 Apr 23;387(10029):1722. link to original article PubMed NCT00532194
    1. Update: Ledermann JA, Embleton-Thirsk AC, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Oza A, Vaughan M, Friedlander M, González-Martín A, Deane E, Popoola B, Farrelly L, Swart AM, Kaplan RS, Parmar MKB; ICON6 collaborators. Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open. 2021 Apr;6(2):100043. Epub 2021 Feb 18. link to original article link to PMC article PubMed
  3. NOVA: Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016 Dec 1;375(22):2154-64. Epub 2016 Oct 7. link to original article contains dosing details in manuscript PubMed NCT01847274
    1. PRO analysis: Oza AM, Matulonis UA, Malander S, Hudgens S, Sehouli J, Del Campo JM, Berton-Rigaud D, Banerjee S, Scambia G, Berek JS, Lund B, Tinker AV, Hilpert F, Vázquez IP, D'Hondt V, Benigno B, Provencher D, Buscema J, Agarwal S, Mirza MR. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 Aug;19(8):1117-1125. Epub 2018 Jul 17. link to original article PubMed
    2. Subgroup analysis: Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. Epub 2019 Jun 7. link to original article link to PMC article PubMed
    3. Update: Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Casado Herráez A, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020 Nov;159(2):442-448. Epub 2020 Sep 25. link to original article PubMed
  4. SOLO2: Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25. link to original article PubMed NCT01874353
    1. Update: Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 May;22(5):620-631. Epub 2021 Mar 18. link to original article PubMed
  5. ARIEL3: Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12. link to original article link to PMC article PubMed NCT01968213
    1. Update: Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 May;21(5):710-722. link to original article link to PMC article PubMed
    2. Update: Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cella D, Meunier J, Goble S, Cameron T, Maloney L, Mörk AC, Bedel J, Ledermann JA, Coleman RL. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. J Clin Oncol. 2020 Oct 20;38(30):3494-3505. Epub 2020 Aug 24. link to original article link to PMC article PubMed
    3. PRO analysis: Peipert JD, Goble S, Isaacson J, Tang X, Wallace K, Coleman RL, Ledermann JA, Cella D. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial. Gynecol Oncol. 2023 Aug;175:1-7. Epub 2023 May 30. link to original article PubMed
  6. FZOCUS-2: Li N, Zhang Y, Wang J, Zhu J, Wang L, Wu X, Yao D, Wu Q, Liu J, Tang J, Yin R, Lou G, An R, Zhang G, Xia X, Li Q, Zhu Y, Zheng H, Yang X, Hu Y, Zhang X, Hao M, Huang Y, Lin Z, Wang D, Guo X, Yao S, Wan X, Zhou H, Yao L, Yang X, Cui H, Meng Y, Zhang S, Qu J, Zhang B, Zou J, Wu L. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial. J Clin Oncol. 2022 Aug 1;40(22):2436-2446. Epub 2022 Apr 11. link to original article PubMed NCT03863860
  7. OReO: Pujade-Lauraine E, Selle F, Scambia G, Asselain B, Marmé F, Lindemann K, Colombo N, Mądry R, Glasspool R, Vergote I, Korach J, Lheureux S, Dubot C, Oaknin A, Zamagni C, Heitz F, Gladieff L, Rubio-Pérez MJ, Scollo P, Blakeley C, Shaw B, Ray-Coquard I, Redondo A; OReO/ENGOT-ov38 investigators. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann Oncol. 2023 Dec;34(12):1152-1164. Epub 2023 Oct 4. link to original article PubMed NCT03106987
Retrieved from "https://hemonc.org/w/index.php?title=Ovarian_cancer_-_null_regimens&oldid=86432"